Why Most Minimum Annual Royalty Clauses Fail to Protect Anyone's Interests

Minimum annual royalties exist for one reason: to prevent a licensee from sitting on a technology forever while the university collects nothing and the invention goes nowhere. Simple enough in theory. In practice, the clause is one of the most consistently misused tools in a license agreement, and the damage runs in both directions.

Photo by Stephanie Douglas on Pexels.

Here's the core problem. Most minimum annual royalty (MAR) figures get set during term sheet negotiations when neither party has a reliable sense of what the technology will actually generate in revenue. The university wants a number high enough to signal seriousness. The licensee wants a number low enough to avoid existential risk in year two. Both sides settle on something that feels like a compromise and move on.

What they've actually done is install a time bomb.

If the MAR is too low, it functions as a de facto parking fee. A company can maintain exclusivity over a university technology for $25,000 per year indefinitely, blocking competitors and keeping the invention off the market. The university's TTO can see exactly what's happening, but the licensee is technically in compliance. There's nothing to trigger a termination provision, nothing to negotiate from, nothing to push the deal forward. The technology sits.

If the MAR is too high, the licensee faces a different trap. Especially for early-stage spinouts, a MAR that was reasonable at signing can become a cliff edge after a funding gap or a delayed regulatory approval. Miss the payment, trigger the cure period, and now both parties are in an ugly conversation nobody wanted. The relationship frays. Lawyers get involved. Sometimes the license terminates over a cash flow problem that had nothing to do with the underlying commercial viability of the technology.

The deeper issue is that most MARs are static numbers attached to a linear commercialization assumption. They don't account for clinical timelines. They don't account for the reality that a medical device or therapeutic might spend four years in regulatory review before generating a dollar of revenue. A flat MAR schedule applied to a biotech spinout is almost always wrong, because biotech commercialization is not flat.

There are better structures. Staged MARs that escalate on a defined schedule tied to development milestones (not just calendar years) give both parties a shared reference point for commercial progress. Some agreements now tie MAR amounts to the licensee's total funding raised, which aligns the payment obligation to the company's actual capacity to pay. Others include a ratchet mechanism: if earned royalties exceed the MAR for two consecutive years, the MAR steps up automatically.

A diagram helps show why the standard approach goes wrong:

graph TD
    A[License Signed] --> B{MAR Too Low?}
    B -->|Yes| C(Licensee Parks Technology)
    B -->|No| D{MAR Too High?}
    D -->|Yes| E(Spinout Cash Flow Crisis)
    D -->|No| F(MAR Matched to Reality)
    C --> G[University Loses Commercialization Upside]
    E --> H[License Terminates Prematurely]
    F --> I[Both Parties Progress Together]

The path to F is narrower than people assume, partly because the negotiation happens before anyone knows enough to set the number well.

One practice that actually helps: build a MAR reset provision into the agreement from the start. If either party can demonstrate a material change in the commercialization timeline, a defined process triggers a renegotiation of the MAR schedule. This sounds like it creates uncertainty, but it does the opposite. It gives both parties a structured way to adapt without defaulting to litigation or termination when the world doesn't cooperate with the original plan.

Tech transfer offices also tend to forget that the MAR clause interacts directly with the exclusivity terms. An exclusive license with a trivially low MAR is essentially a gift of market rights with no meaningful performance obligation attached. If a university is granting exclusivity, the MAR should function as a genuine proxy for commercial diligence, not a token payment to stay current on the agreement. That means thinking about what the market opportunity is actually worth and working backward to a number that reflects real stakes.

Licensees, for their part, sometimes push for low MARs without fully thinking through what they're signaling to the university. A company that negotiates its MAR down to the floor in the first conversation has told the TTO something about how seriously it takes the commercial obligation. That impression persists through the relationship in ways that matter when flexibility is needed later.

Setting a MAR is really a negotiation about shared expectations for commercial performance. Treat it that way, build in adaptation mechanisms, and tie it to something other than a calendar page turning. The clause is small. Its consequences rarely are.